Carlsmed Earnings Call Transcripts
Fiscal Year 2026
-
Aprevo's digital, AI-driven spine surgery platform has demonstrated strong clinical outcomes, including a 74% reduction in reoperations, and is expanding rapidly in both lumbar and cervical markets. Elevated reimbursement, robust surgeon adoption, and new product launches support a 44% growth outlook for 2024.
-
Rapid revenue growth and strong clinical validation drive adoption of a personalized spine surgery platform, now expanded to both lumbar and cervical procedures. New reimbursement wins and technological innovations support continued U.S. market expansion.
Fiscal Year 2025
-
Achieved 86% revenue growth in 2025, driven by strong lumbar platform performance and new cervical product launches. Gross margins expanded to 75.3%, and 2026 revenue is guided to grow 44% at the midpoint. Cash position remains strong after a successful IPO.
-
A next-generation med tech platform for spine surgery has demonstrated a 74% reduction in reoperation rates and is expanding from lumbar to cervical procedures, targeting a combined 800,000 annual U.S. cases. Enhanced reimbursement, rapid production, and a capital-light model drive strong growth and adoption.
-
Q3 2025 saw 98% revenue growth, 76% gross margins, and a 70% increase in surgeon users, with strong clinical data supporting reduced revision rates. Full-year revenue guidance was raised to $49–$50 million, and the company is well-positioned for the upcoming cervical fusion launch.
-
Q2 2025 revenue nearly doubled year-over-year to $12.1 million, driven by strong surgeon adoption and procedure growth. Full-year revenue is guided to $45.5–$47.5 million, with continued expansion in both lumbar and upcoming cervical fusion markets.